Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

23.03.2023 - Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that ... Seite 1

Related Keywords

Australia ,Australian ,Joseph Tucker ,Jemma Lawson ,Enveric Bioscience ,Nasdaq ,Australia Therapeutic Goods Administration ,Enveric Therapeutics Pty Ltd ,Enveric Biosciences Inc ,Enveric Biosciences ,Avance Clinical ,Enveric Therapeutics Pty ,New Chemical Entity ,Therapeutic Goods Administration ,Project Operations ,